Human Mesenchymal Stem Cells (T-MSC™) for treatment of autoimmune disease
ImStem Biotechnology, Inc., is a biotech company, incorporated and operating in Connecticut. ImStem is focusing on developing off-the-shelf cell-therapy product derived from human pluripotent stem cells(hPSC) for regeneration and autoimmune diseases treatment. To improve the efficacy of mesenchymal stem cell (MSC)-based therapy, we developed a new technology to derive MSCs from hPSC, so called T-MSC. With the support from Connecticut Regenerative Medicine Research Fund and angel investors, an IND targeting multiple sclerosis has been filed with our T-MSC technology based cell product IMS001 in 2019.
Xiaofang Wang, VP/CTO
Michael Men, President/CEO